Fundraising Fox

AbbVie

NYSE: ABBV

North Chicago, US · Founded 2012 · Delaware corporation · 2 known investors

Biotech

Founders & leadership

TA
Thomas A. HurwichExecutive
TJTimothy J. Richmond
Timothy J. RichmondExecutive
HGHenry Gosebruch
Henry GosebruchinExecutive
AS
Azita Saleki-GerhardtinExecutive
ME
Michael E. SeverinoExecutive
WC
William ChaseExecutive
RARichard A. Gonzalez
Richard A. GonzalezinExecutive

Board

EM
Edward M. LiddyBoard director
GF
Glenn F. TiltonBoard director
RS
Roxanne S. AustinBoard director
FH
Frederick H. WaddellBoard director
RJ
Robert J. AlpernBoard director

Investors · 2

Artis VenturesreportedSan Francisco · $50K – $25Mvia Stuart Peterson · quoted
Founders FundreportedSan Francisco · $500K – $5M

Reported raises · per SEC filings

Form D private placements

$3.8B disclosed across 1 round · 2016

▶$3.8BraisedMay 2016 · 39 investors · Pharmaceuticals
Rule 506(b)
AbbVie Acquires Founders Fund-Backed Stemcentrix for $6Btechnologyreview.com · May 2016AbbVie agrees to buy Peter Thiel-backed biotech Stemcentrxmarketwatch.com · Apr 2016
Officers, directors & promoters on the filing
  • Thomas A. HurwichExecutive Officer
  • Edward M. LiddyDirector
  • Timothy J. RichmondExecutive Officer
  • Glenn F. TiltonDirector
  • Henry GosebruchExecutive Officer
  • Azita Saleki-GerhardtExecutive Officer
  • Roxanne S. AustinDirector
  • Michael E. SeverinoExecutive Officer
  • Frederick H. WaddellDirector
  • William ChaseExecutive Officer
  • Richard A. GonzalezExecutive Officer, Director
  • Robert J. AlpernDirector
  • William H.L. BurnsideDirector
  • Brett J. HartDirector
  • Carlos AlbanExecutive Officer
  • Edward RappDirector
  • Laura J. SchumacherExecutive Officer
Offering amount
$3.8B
Amount sold
$3.8B
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Acquisitions · 1

Early investors' stakes continue via these deals
Celsius Therapeutics

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine. Acquired by AbbVie Inc. in June 2024.

In the news

Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?finance.yahoo.com · Aug 2026Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. | The Motley Foolfool.com · Aug 2026AbbVie Raises $9 Billion Debt to Fund Acquisition - The Globe and Mailtheglobeandmail.com · Aug 2026Wells Fargo raises Abbvie stock price target on HS drug potential By Investing.cominvesting.com · Aug 2026AbbVie (ABBV) Stock May Be 45% Undervalued On Raised 2026 Outlook - Simply Wall St Newssimplywall.st · Aug 2026AbbVie Acquires Founders Fund-Backed Stemcentrix for $6Btechnologyreview.com · May 2016AbbVie agrees to buy Peter Thiel-backed biotech Stemcentrxmarketwatch.com · Apr 2016

Frequently asked questions

Who are AbbVie's investors?
AbbVie's investors include Artis Ventures, Founders Fund.
How much funding has AbbVie raised?
AbbVie has disclosed $3.8B raised across 1 round.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, US.